IL-12 GENE THERAPY OF TUMORS

Abstract: In an approach to genetic therapy for treating tumors, a genetic construction encoding the p35 and p40 subunits of the cytokine IL-12 is delivered into cells of individuals in need of therapy so as to express IL-12 in cells and to cause regression of established tumors.

Description: IL-12 GENE THERAPY OF TUMORS Field of the Invention The present invention relates generally to the field of treatment of tumors, and relates in particular to the direct delivery into skin cells of a genetic construct containing the I -12 gene. Background of the Invention Interleukin (IL) 12, formerly termed natural killer cell-stimulatory factor or cytotoxic lymphocyte maturation factor, is a disulfide-linked heterodimeric cytokine composed of 35-and 40-kDa subunits; the subunits are commonly designated "p35" and "p40". The complimentary DNAs encoding the p35 and p40 subunits from both the mouse and humans have been sequenced and cloned, and both human and mouse IL-12 have been shown to act as growth factors for natural killer ("NK") cell and T-cell, JQ vitro and j i vivo. Furthermore, IL-12 has also proven to be effective in regression and complete disappearance of murine tumors. Tahara et al., Cancer Research 54 (1) : 182-9, 1994; Brunda et al., J. EXP. MED. 178 (4): 123-30, 1993. However, because IL-12 has a short half life in vivo, frequent injections of the cytokine are needed to achieve therapeutic effects. Moreover, relatively large quantities of IL-12 (in the range of 1-10 g/day) are typically required. Therefore, administration of recombinant IL-12 often resulted in toxicity. IL-12 gene therapy using retroviral vectors is underway in several laboratories, and its anti-tumor effect has been demonstrated. Lotze, M.T., et al. , J " . Cell . Biochem. , p.184, 1993.; Robbins, et al . , Cancer Gene Therapy 1(2) :147, 1994. In the Lotze, et al. study, the genes for I -12 p35 and p40 subunits were inserted into NIH 3T3 fibroblasts. The fibroblasts were used to deliver IL-12 at the site of tumors, delaying growth of a variety of murine tumors. In the Robbins, et al . study, the direct delivery of IL-12 to several different mouse tumor lines by retroviral- mediated transduction prior to inoculation or to fibroblasts that were then coadministered with tumor cells resulted in inhibition of tumor growth as well as in the induction of antitumor immunity. However, to date, it was not possible to cause reliable regression of established tumors and their spontaneous metastases using direct IL-12 gene therapy. Summary of the Invention The present invention is summarized in that an anti-tumor response can be effected after transfer to a mammalian animal of a DNA molecule that encodes the cytokine IL-12. In one aspect the invention is a method to treat tumors in an animal, preferably a mammal and most preferably a human, by genetic therapy. In the method, copies of a foreign genetic construction are prepared. The genetic construction includes a promoter operative in cells of the animal and protein coding regions encoding both the p35 and p40 subunits of the cytokine IL-12. The foreign genetic construction is then physically delivered into the epidermis of the tumor- bearing animal in need of such genetic therapy. In another aspect, the invention provides a genetic construct for treating tumors. The construct is provided by operatively joining DNA sequences encoding the p35 and p40 subunits of the cytokine IL-12 to a promoter effective in the animal's cells. The construct is suitable for transduction into cells of an animal by, for example, a particle-mediated transfection process. It is an object of the present invention to enable the treatment of tumors through the use of an IL-12 genetic construct. It is a feature of the present invention in that it is adapted to either epidermal or mucosal delivery of the genetic construct. It is an advantage of the genetic treatment of the present invention that it is inherently safe, not painful to administer, and should not result in adverse consequences to treated individuals. It is a further advantage of the genetic treatment of the present invention that the genetic treatment is effective even when delivered to a site distant from the tumor, and immunological memory is retained after genetic treatment ceases. Other objects, advantages and features of the present invention will become apparent from the following specification. Brief Description of the Drawings Fig. 1 is a plasmid map of the IL-12 plasmid pWRG3169. Fig. 2 is a plasmid map of the IL-12 plasmid pWRG3196. Fig. 3 is a graph presenting tumor growth patterns in I -12 gene-treated and control mice. Fig. 4A-4F are graphs presenting change in diameter of various induced solid tumors after treatment using IL-12 genes. Detailed Description of the Invention The present specification describes a method to treat tumors by delivering a genetic construct encoding the p35 and p40 subunits of IL-12 protein into the epidermis of a patient at the tumor site. The tumors can be solid tumors or metastatic or disseminated tumors, and can be microscopic or visible with the naked eye. Once the construct is delivered, the heterodimeric IL-12 cytokine is expressed, resulting in the creation of an anti-tumor response in treated individuals, even when the tumor is far removed from the delivery site. In order to achieve the genetic treatment sought of the present invention, an IL-12 genetic construction is created in which the IL-12-encoding genes are placed under the control of a promoter operative in the cells of a target mammalian animal. When transfected into cells of a treated animal, a suitable construct causes expression of the IL-12 protein. IL-12 protein is actually a heterodimer that includes a 35 kDa (p35) and a 40 kDa (p40) subunit. Each subunit is encoded by a distinct gene. The IL-12 p35- and p40-encoding DNA sequences can be obtained or derived from a mammalian animal source, preferably from a human source. A full-length DNA sequence encoding human IL-12 subunits has been published by Gubler, et al., Proc. Natl. Acad. Sci. USA 88: 4143-4147, 1991. The published human nucleic acid and amino acid sequences of a p35 subunit are available at GenBank Accession number M65271. Similarly, the nucleic acid and amino acid sequences of a human p40 subunit are also available at GenBank Accession number M65272. Alternatively, the IL-12 subunit-encoding sequences can be obtained from any other non-human animal that produces I -12. The IL-12 subuni -encoding sequences may be obtained or derived from other species which demonstrate sufficient sequence identity to be functionally equivalent to human IL-12. For example, IL-12 is known to be produced by mice. Mice sequences were used in the example constructs reported herein. A p35-encoding DNA is reported at GenBank Accession number M86672. The p40-encoding DNA is also available from GenBank. Also, in vitro-synthesized coding sequences encoding IL-12 p35 and p40 subunits can readily be prepared in quantities sufficient for molecular cloning using standard recombinant molecular biological techniques, including PCR amplification and hybridization, using the published DNA sequence as a guiding template. It may also be possible to further modify the subunit-encoding DNA molecules and protein subunits disclosed herein, while still maintaining the anti- tumor activity of the present invention. The present invention is intended to include truncated natural IL- 12 DNA having the nucleic acid sequences described herein, as well as all altered, varied and modified forms of the DNA. These can include, but are not limited to substantially homologous DNA fragments having additions, deletions, and point mutations, relative to the disclosed nucleic acid sequences including truncation at the 5' and/or 3' end. A substantially homologous DNA fragment is one wherein the fragment encodes a polypeptide that exhibits significant antitumor activity and/or regression after delivery, even if such DNA differs in nucleic sequence or encodes a protein that differs in amino acid sequence from the DNA fragments or proteins disclosed herein. Anti-tumor activity of such truncated DNA molecules can be monitored as described below. One skilled in the art will recognize that certain silent changes to the nucleic acid sequence have no effect on the amino acid encoded by a particular triplet. Even certain amino acid changes that do not affect, or only somewhat affect, the IL-12 activity of the encoded protein may be used within the scope of the invention. Any nucleic acid or amino acid sequence that results in anti-tumor activity that is at least 75% of the activity obtained using the murine IL-12 (mIL-12) genes tested as described in the following Examples may be used in the present invention. Of course, if the gene encoding an IL-12 protein is engineered into a genetic construct for delivery into a host of a species other than that from which the gene derives, an immune response may occur after gene transfer. However, one skilled in the art will understand that by modifying the,nucleic acid sequence of the mature I -12 portion of the delivery gene, it is possible to eliminate such effect. To properly express the IL-12 subunit genetic sequences in transfected cells, a promoter sequence operable in the target cells is needed. Several such promoters are known for mammalian systems which may be joined 5', or upstream, of the coding sequence for the protein to be expressed. A preferred promoter is the CMV promoter, the sequence of which is well known and which has been published at Cell, 41:521-530 (1995) . A downstream transcriptional terminator, or polyadenylation sequence, may also be added 3' to the protein coding sequence. A preferred polyadenylation sequence is the bovine growth hormone poly A region, the sequence of which is known. Splice donor and splice acceptor (SD/SA) sites, such as the SV40 SD/SA, may also be positioned in the construct if desired, as may an internal ribosome entry site (IRES), such as the IRES cloned from encephalomyocarditis virus. As the inventors describe in more detail in the Examples, below, it has been determined that expression of the two protein-encoding sequences from separate transcription units on a single plasmid results in significantly higher protein levels than are observed when bicistronic expression of the genes is driven from a single promoter. Thus, for purposes of this invention, it is preferred that each coding region be provided with a separate promoter. Introduction of the Genetic Material In the present invention, a suitable genetic construct encoding IL-12 protein subunits is transferred into the susceptible individual. A genetic treatment can be delivered in a non-invasive manner to a variety of susceptible tissue types in order to achieve the desired immunological response in the individual. It is herein disclosed that when treating tumors with the IL-12 genetic construct, the preferred target cells are epidermal cells rather than cells of deeper skin layers such as the dermis. Epidermal cells are preferred recipients of the IL-12 genetic construct because they are the most accessible cells of the body. Patients in need of such genetic therapy may advantageously, therefore, be treated non-invasively. Moreover, quite unexpectedly, and contrary to what some might think, epidermal delivery of the IL-12 gene successfully treats tumors far removed from the delivery site, and furthermore, generates systemic anti-tumor immunity, immunological memory, and cytotoxic responses. Therefore, epidermal delivery is well particularly suited for non-invasive delivery of the I -12 genes. Inasmuch as IL-12 genetic construct treatment has proven successful in eliciting successful anti-tumor responses following gene gun-based IL-12 genetic construct delivery to the skin, it is also probable that non-invasive delivery of the IL-12 genetic construct to mucosal surfaces will result in successful treatment responses as well. It is also specifically envisioned that aqueous droplets containing naked IL-12 DNA can be delivered directly into the tissues of the individual sought to be treated. At some frequency, such "naked" DNA will be taken up in the treated tissues. The preferred transfer means for non-invasive delivery is an accelerated particle gene transfer device, although any means that can reliably transfer the construct into the suitable target sites (epidermis or mucosal tissue) is acceptable. The technique of accelerated-particle gene delivery is based on the coating of genetic constructions to be delivered into cells onto extremely small carrier particles, preferably gold particles, which are designed to be small in relation to the cells sought to be transformed by the process. The gold particles may be beads or spheres or amorphous gold. All are suitable for use in the present invention. Reference herein to particles is intended to include all such forms. Amorphous gold, such as Englehard microcrystalline gold, has been demonstrated in other biological target systems to achieve higher delivery into target cells than other types of gold. Without regard to the type of particle acceleration apparatus or suitable particles used, the coated carrier particles are then physically accelerated toward the cells to be transformed such that the carrier particles lodge in the interior of the target cells. This technique can be used either with cells in vitro or in vivo. At some frequency, the DNA which has been previously coated onto the carrier particles is expressed in the target cells. This gene expression technique has been demonstrated to work in procaryotes and eukaryotes, from bacteria and yeasts to higher plants and animals. Thus, the accelerated particle method provides a convenient methodology for delivering genes into the cells of a wide variety of tissue types, and offers the capability of delivering those genes to cells in situ and in vivo without any adverse impact or effect on the treated individual. The accelerated particle method is also preferred in that it allows a genetic treatment construction to be directed both to a particular tissue, and to a particular cell layer in a tissue, by varying the delivery site and the force with which the particles are accelerated, respectively. The general approach of accelerated particle gene transfection technology is described in U.S. Patent No. 4,945,050 to Sanford. An instrument based on an improved variant of that approach is available commercially from BioRad Laboratories. An alternative approach to an accelerated particle transfection apparatus is disclosed in U.S. Patent No. 5,015,580, which, while directed to the transfection of soybean plants, describes an apparatus which is equally adaptable for use with mammalian cells and intact whole mammals. U.S. Patent 5,149,655, describes a convenient hand-held version of an accelerated particle gene delivery device. Other such devices can be based on other propulsive sources using, for example, compressed gas as a motive force. Gene gun delivery allows for precise control over the level and form of IL-12 production in a given epidermal site because intracellular DNA delivery can be controlled by systematically varying the number of particles delivered and the number of plasmid copies per particle. This precise control over the level and form of cytokine production may allow for control over the nature of the resultant response. The term transfected is used herein to refer to cells which have incorporated the delivered foreign IL- 12 genetic construction, whichever delivery technique is used. The term transfected is used in preference to the term transformation, to avoid the ambiguity inherent in the latter term, which is also used to refer to cellular changes in the process of oncogenesis. The present invention will be more fully understood by reference to the following examples, which are intended to be merely exemplary of the invention. In the examples, mice have been used as a model recipient for the IL-12 expression construct. Mice are the standard animal model for extrapolation to human tumors, and general FDA policy requires researchers to demonstrate efficacy of a proposed cancer treatment in mouse models before undertaking clinical trials. EXAMPLES Construction of Plasmids Encoding murine IL-12 Two murine IL-12 constructs have been used, each of which encodes both the p35 and the p40 subunits of mIL-12. These subunits were cloned from a mouse spleen cDNA library. All plasmids were made with the express purpose of increasing cytokine gene expression of I - 12, and with the immediate intended use in a cancer gene therapy program. Plasmid pWRG3169 is a tandem plasmid encoding both mIL-12 subunit genes. A map of plasmid pWRG3169 is provided in Fig. 1 and the complete nucleotide sequence of the plasmid is presented in SEQ ID NO:l. The p35 and p40 products of the plasmid are reported as SEQ ID NO:2 and SEQ ID NO:3, respectively. Each subunit- encoding gene is under the transcriptional control of a separate cytomegalovirus (CMV) promoter. An SV40 splicing donor/splicing acceptor (sa/sd) is provided between each subunit-encoding segment and its CMV promoter. Just downstream (3') to each subunit- encoding segment is a bovine growth hormone polyadenylation signal (bGH pA) . Each unit (promoter - sa/sd - coding region - poly A signal unit) is transcribed in series (i.e., in the same direction) from the plasmid. The pUC19 plasmid backbone is derived from a Bluescript * SK(+) vector with an ampicillin resistance gene which is available commercially from Stratagene Cloning Systems, La Jolla, CA. Plasmid pWRG3196 is a bicistronic plasmid encoding both subunits of mIL-12. A map of plasmid pWRG3196 is provided in Fig. 2 and the complete sequence is shown in SEQ ID N0:4. The p35 and p40 products of the plasmid are reported as SEQ ID NO: 5 and SEQ ID NO:6, respectively. The pUC19 plasmid backbone was derived from a Bluescript SK(+) vector with an ampicillin resistance gene. This vector contains a single cytomegalovirus (CMV) promoter, SV40 splicing donor/splicing acceptor, and bovine growth hormone polyadenylation signal. Both the p35 and p40 genes are provided downstream from the sd/sa site and upstream from the SV40 poly A site. The p35 gene is upstream from (i.e., closer to the promoter than) the p40 gene. Between the p35 and p40 genes is an internal ribosome entry site element (IRES) cloned from encephalo yocarditis virus. The IRES element is a non- coding region which functions as an internal entry point for initiation or continued translation by eukaryotic riboso es. Both pWRG3169 and pWRG3196 direct expression of mIL-12. From a molecular standpoint, however, the bicistronic IRES vector (pWRG3196) produces a single mRNA, whereas the tandem vector (pWRG3169) produces separate mRNA for p35 and p40. In gene expression studies, the present inventors discovered that pWRG3169 induced at least twice the expression of the bicistronic pWRG3196, both in vivo and in vitro. For example, when the pWRG3169 and pWRG3196 vectors were transfected separately into B16 tumor cells in vitro, or into murine skin in vivo. 3-8 fold higher mIL-12 protein expression levels were observed when the pWRG3169 vector was transfected. Still lower expression levels were observed when two separate vectors, each encoding one of mIL-12 subunit proteins, were transfected. Importantly, biologically active IL-12 cytokine was detected locally after transfer to B16 murine melanoma cells and after skin bombardment using a particle acceleration instrument. When 1.25 μg of pWRG3169 DNA was delivered by particle acceleration into 1 x 10* B16 cells, 49.8 ± 10.2 ng/ml were detected after 24 hours. Twenty-four hours after skin was bombarded four times with a total of 5 μg of pWRG3169 DNA, 266 ± 27.8 pg of IL-12 were detected per 0.172 ± 0.026 gm of tissue in a standard 1.5 x 1.5 cm 2 full thickness skin biopsy which contained four treated sites. The level of IL-12 was determined using a cell proliferation assay using murine Con-A-activated splenocytes as described by Schoenhaut, et al. , J. Immunol ■ 148:3433 (1992) . It is envisioned that similar expression-competent vector constructs can be created which will include human p35 and human p40, the sequence of which are provided herein) for use in cancer gene therapy clinical studies. In addition, future vectors will include Intron A and possibly an episomal element such as EBNA-1 from Epstein-Barr virus. Implantation of Tumors in Mice Renal cell adenocarcinoma (Renca) and methylcholanthrene-induced fibrosarcoma (MethA) tumor cell lines, are syngeneic in Balb/c mice. L5178Y lymphoma and P815 astocytoma are syngeneic in DBA/2 mice. SA-1 sarcoma and B16 melanoma are syngeneic in A/Sn and C57B1/6, respectively. Tumor cell lines were maintained in vitro under established conditions. To induce tumor formation, suitable recipient mice were shaved in their abdominal area and were injected with lxlO 6 tumor cells in 50 μl of PBS intradermally (except 10 s B16 cells were delivered) . Tumor growth was monitored 2-3 times a week by measuring two perpendicular tumor diameters using calipers. Use of mIL-12 Plasmids in Tumor Treatment The experiments utilized a helium-pulse particle acceleration device of the type described in published PCT application number PCT/US95/00780 (Publication number WO 95/19799). Plasmid DNA was precipitated onto 2 micron gold particles using PEG/CaCl 2 or spermidine/CaCl 2 . Particles were suspended in a solution of 0.1 mg/ml polyvinylpyrrolidone in absolute ethanol. This DNA/gold particle preparation was coated onto the inner surface of Tefzel tubinq as described in Publication No. WO 95/19799. The tubing was then cut into cartridges of 0.5 inch length, to achieve delivery of 0.5 mg gold and 1.25 μg plasmid DNA per bombardment with a single cartridge. The deposited DNA-coated particles were lifted from the cartridges and were delivered into mouse epidermis under the force of a 300 psi helium pulse. Histologic examination and standard immunohistochemical analyses using a monoclonal anti-IL-12 antibody demonstrated that under this force, the gold particles primarily penetrated to the epidermal cell layers of the mouse skin tissue, but did not penetrate into the underlying tumor cells, and, likewise, that transgenic mIL-12 was expressed only in epidermal cell layers. At each transfection timepoint, individual mice received four bombardments with the mIL-12 DNA genetic construct or with control DNA (pCMVLuc; Cheng, et al. , 90 Proc. Natl. Acad. Sci. USA 4455 (1993)) . One bombardment was directly over the tumor, and three additional bombardments were evenly spaced around the circumference of the tumor in a triangle pattern. Regression of Murine Renca and MethA Tumors in Mice Balb/c mice were inoculated as described above with 1 x 10 6 Renca or MethA tumor line cells. At the indicated time after inoculation, the tumor injection sites were bombarded once per day for 3-5 days with pWRG3196, with pWRG3169 or with control plasmid pCMVLuc, starting on day 7 of tumor growth (in the first experiment, bombardment started on days 1, 4, or 7 of tumor growth) . The results of four preliminary experiments are presented in Table 1. In the first experiment, 3 of 7 (42%), 3 of 6 (50%), and 5 of 7 (71%) mice treated on days 1-5, 4-8, and 7-11, respectively, completely rejected their tumors, whereas all control (untreated) mice were sacrificed by day 18 due to progressive tumor growth. The tumor growth pattern in IL-12 gene-treated and control mice is presented in Figure 3. It can be seen that regression started several days after terminating the treatment, suggesting that the anti-tumor effect is immunologically-mediated. Moreover, it is important to note that in this and other experiments, in situ bombardment with the mIL-12 encoding plasmid caused regression of established (5-10 mm in diameter) solid murine tumors. In the second experiment, mIL-12 treatment caused rapid regression in the tumors in all mice. Due to the heavy skin bombardment, however, 28% of mice transfected with the control gene also rejected their tumors. In order to eliminate this nonspecific and anti-tumor effect, the duration of the treatment was reduced to three bombardments every other day. Indeed in the third experiment, all tumors bombarded with the control gene grew progressively, whereas 62% of mice bombarded with the mIL-12 genetic construct rejected their tumors. In experiment 4, MethA sarcoma was used instead of Renca tumor and showed similar high sensitivity to IL- 12 gene treatment. - 15 - Table 1 Rejection of intradermal murine tumors following IL-12 gene therapy Experiment Tumor Treatment/ No. of Rejection Days mice (%) tumor- free/ total 1 Renca None 0/7 0 pIL-12 » /l-5 3/7 42 pIL-12 a /4-8 3/6 50 pIL-12 a /7-ll 5/7 71 2 Renca pCMVLUC/7-11 2/7 28 pIL-12 b /7-ll 7/7 100 3 Renca pCMVLUC/7,9,11 0/8 0 pI -12 b /7,9,ll 5/8 62 4 MethA pCMVLUC/ 1/8 12 7,8,10,11 6/8 75 pIL-12 b / 78,10,11 a - pWRG3196 (IRES); b - pWRG3169 (Tandem) Additional demonstrations of tumor regression The present inventors also used the IL-12 treatment method of the present invention with other murine tumors, as described below. In all cases, reduction of tumor growth was observed following mIL-12 gene transfection. It is known that certain murine immunogenic tumors can induce a T cell-mediated immune response which is best detected on days 7-9 of tumor growth in defined tumor models (17) . Therefore mIL-12 cDNA treatments were begun at 7 days post-implantation of tumor cells, to enhance the already activated endogenous antitumor immune response. Using this experimental strategy, the in vivo delivery of the chimeric IL-12 genes into skin tissues overlying established 7-day tumors resulted in complete tumor regression or suppression of tumor growth in 4 tumor models. In suitable mice bearing Renca, L5178Y, MethA or Sa-1 tumors, complete tumor regression was achieved in 87.5% (7/8), 87.5% (7/8), 57% (4/7) and 37.5 (3/8) of test mice, respectively. Nearly identical results were achieved with Renca tumors after a single IL-12 cDNA treatment on day 7. The effect of mIL-12 gene therapy on tumor growth in these 4 tumor models are shown in Fig. 4. Furthermore, in mice bearing P815 mastocytoma or B16 melanoma, a significant suppression of tumor growth was achieved (Fig. 4) . For example, on day 13 post P815 tumor cell implantation, the mean tumor diameter in mice treated with pWRG3169 was 8.89 ± 0.27, as opposed to 12.28 ± 0.46 mm for the pCMVLuc control gene in the same expression plasmid (p<0.00l) . Likewise, on day 15 post B16 tumor cell implantation, tumor diameter in mice treated with pWRG3169 was 6.30 ± 0.045 as opposed to 11.8 ± 0.31 mm for the pCMVLuc control gene plasmid (p<0.001) . For these two weakly immunogenic tumor systems, it is unclear whether modified gene transfer regimes or schedules can improve the therapy and result in tumor regression, and this apparently warrants systematic evaluations in future studies. The mIL-12 gene therapy experiments were repeated 5 times with the Renca tumor system, 4 times with MethA and P815 tumors, 3 times with the B16 tumor, and once with L5178Y tumor model, and similar results were obtained. At each treatment, mice received four transfections with IL-12 DNA (circles) or pCMVLuc DNA (squares) . The arrows in Fig. 4A - 4F indicate the days post tumor implantation on which treatment was carried out. Each group contained 7-8 mice, except the B16 tumor model which contained 12 mice per group. It is important to note that for all tested mouse tumor models, the tumors were already well-established at the beginning of the therapy, and had reached 5-8 mm in diameter. To our knowledge, this is the first evidence that IL-12 gene therapy can cause a complete regression of large, established tumors. Previous studies have shown that IL-12 gene therapy using retroviral vectors resulted in prevention of tumor development, or regression of small, 3-day-old MCA207 sarcomas in 33% of treated mice. It is also noteworthy that only 1-4 days of therapy (using 4 bombardments per tumor site on each day of therapy) resulted in tumor regression or growth suppression in virtually all of our experiments. In previous studies using recombinant protein therapy, tumor regression required daily injections of IL-12 at doses from 0.1 to 10 μg for 1 weeks, or 5 days a week for 4 weeks. In conjunction with our previous findings using other cytokine genes, the results presented in Figs. 1, 2 suggest that transgenic IL-12 production by normal epidermal cells in the vicinity of the tumor can be responsible for the antitumor effect of IL-12 gene therapy. IL-12 induced Tumor regression involves CD8 * cells The observed tumor regression depended upon the presence of CD8* cells. In vivo depletion of CDΘ* T cells, but not the depletion of CD4 * T cells, abrogated the effect of mIL-12 gene therapy. To demonstrate this, Balb/c mice were injected intrader ally with lxlO 6 Renca cells. Skin was transfected with IL-12 or pCMVLuc cDNA expression vectors on days 7, 9 and 11 post tumor implantation. Anti-CD4 mAb (clone GK1.5) or anti-CD8 mAb (clone 2.43), both obtained from Trudeau Institute, Saranac Lake, NY, were administered intraperitoneally on days 8 (300 μg/mouse) and 12 (150 μg/mouse) after tumor implantation. Control groups included mice that were treated with the IL-12 gene and received rat IgG (Sigma) at the same doses and schedule as the anti CD8-and CD4 mAb, or mice treated with the pCMVLuc gene instead of the IL-12 gene. The anti-CD4 and Anti-CD8 mAb used in this study caused depletion of more than 90% of relevant T cell subsets in mice for 4- 5 days following a single injection. Tumor mass for 8 mice per group continued to enlarge when CD8* T cells were eliminated, but tumor regression or elimination was observed when CD4 * T cells were removed, or when rat IgG was injected. These data are in agreement with the findings of Brunda et al . , J. Exp. Med. 178(4) :123- 30 (1993) that tumor regression caused by recombinant IL-12 is mediated by CD8 * T cells, but not CD4* T cells. In fact, depletion of CD4 * T cells with anti-CD4 monoclonal antibody (mAb) appeared to result in slightly accelerated tumor regression, implying that CD4* T cells may suppress the anti-tumor effect of IL- 12 in this tumor model. Indeed, it has been shown that established tumors induce Th2-like CD4 * T suppressor cells, which can inhibit CD8* T cell-mediated immune responses. The beneficial effect of anti-CD4 mAb treatment for tumor immunotherapy with recombinant IL-2 protein or IL-12 gene has been previously reported. Supporting data show that IL-12 protein can activate tumor-specific CD8 * T cells in vitro, and mediate an anti-suppressive effect on Th2 CD4 * T cells in vivo. Gene Gun Delivery of the IL-12 Gene into the Tumor Site Causes Systemic Anti-Tumor Effect Resulting in Reduction of Growth of a Distant Tumor The observation that tumor regression caused by local IL-12 gene therapy requires CD8* T cells suggest that local IL-12 gene delivery might result in a systemic antitu or effect. This hypothesis was tested using the P815 tumor system, in which tumor cells metastasize into the visceral organs several days after the intradermal implantation, thereby causing the death of the mice even when the primary tumor has been surgically removed. DBA/2 mice were injected intradermally with lxlO 6 P815 cells. Skin tissues overlying and surrounding the target tumor were treated with pWRG3169 delivered by particle acceleration (8 mice/group) , or pCMVLuc (5 mice/group) on days 12 and 14 after tumor cell implantation. Surgical excision of the tumor was performed on day 15, when tumor size reached about 13 mm in diameter. Additional transfections of control and test constructs into skin on both sides of the abdomen were performed on days 16, 18 and 20 post implantation. All mice treated with pCMVLuc died in 28.0 ± 0.6 days after tumor cell implantation. Macroscopic examination revealed that death was caused by spontaneous metastases of tumor cells into the internal organs, primarily the liver. mIL-12 gene therapy effectively prolonged the survival of mice (survival time 41.4 ± 4.9 days, p<0.05), and 1 of 8 mice was "cured. " This experiment was repeated without additional transfections post tumor excision, and showed that all of the Luc cDNA treated mice (n=ll) died in 43.9 ± 7.1 days, whereas 5 or 12 (41.6%) IL-12 gene therapy- treated mice survived for at least 180 days and thus were considered "cured." These results suggest that local delivery of IL-12 gene into the skin tissues overlying and surrounding the primary tumor can augment systemic antitumor immune response and lead to eradication of established spontaneous metastases. Balb/c mice were injected intradermally with 10 6 Renca cells, both in the left and right sides of the abdomen. The tumors on the right side were bombarded with either pWRG3169 or pCMVLuc on days 5, 7, and 9 of tumor growth. IL-12 gene therapy resulted in significant growth reduction in the untreated (left) tumor as compared with the growth of untreated tumors in control mice (tumor diameter on day 22: 9.58 ± 1.82 and 13.18 ± 2.03, respectively; n=8 mice/set, p<0.005) . A similar experiment was performed in which the L5178Y tumors on the right side of the abdomen were bombarded with either pWRG3169 or pCMVLuc on days 3 and 6 of tumor growth. In this experimental setting, IL-12 gene therapy resulted in complete tumor regression of the treated (right) as well as untreated (left) tumors in all mice (n=8) . An additional experiment has shown that IL-12 gene bombardment of the skin, away from the tumor vicinity, does not affect tumor growth. These results suggest that local activation of immune cells at the tumor site during IL-12 gene therapy generates systemic anti-tumor immunity. Mice that Rejected the Tumors Following IL-12 Gene Therapy Develop Tumor-Specific Immunological Memory A. Rejection of secondary tumor challenge followed IL-12 gene therapy. Balb/c mice that rejected Renca or MethA tumors following IL-12 gene therapy were injected one month later with lxlO 6 of both Renca cells and MethA cells on the right and the left side of abdomen, respectively. As a control, the tumor cells were injected into age-matched naive Balb/c mice (5-8 mice per group) . Mice that rejected intradermal Renca (Group A) or MethA tumors (Group B) following IL-12 gene therapy, or control naive mice, were injected into the right side of the abdomen with Renca cells, and into the left side of the abdomen with MethA cells. Whereas all control mice developed both tumors, mice of Group A developed MethA tumors but not Renca tumors, and vice versa, that is, mice of Group B developed Renca tumors but not MethA tumors. B. Induction of CTL activity in mice that rejected tumors following IL-12 gene therapy. Tumor- specific CTL were generated in vitro as described by Rakhmilevich et al. , Int. J. Cancer. 55:338 (1993) . Spleen cells (5xl0 6 ) , derived from Balb/c mice that had rejected Renca tumors due to IL-12 gene therapy and had remained tumor-free for two months, or from age-matched naive mice, were co-cultured with 5xl0 4 mytomicin-C- treated Renca cells in 24-well culture plates in complete RPMI-1640 media. After culturing for 5 days in vitro, graded numbers of viable effector cells and 51 Cr-labeled Renca cells (10 4 ) were placed into the wells of round-bottomed 96-well plates. After incubating for 4 hr at 37°C, radioactivity in supematants was determined. Mean ± SEM of 4 mice per group. Spleen cells from IL-12 gene-treated mice generated 3-4-fold higher levels of CTL activity than spleen cells from naive mice (p<0.005) . These results indicate that IL-12 gene therapy generates systemic anti-tumor immunity. In a similar study, using spleen cells from mice that had previously rejected L5178Y tumors, CTL generated were able to lyse L5178Y cells but not syngeneic P815 cells. All in all, the results indicate that IL-12 gene therapy with a particle-mediated gene transfer instrument is effective against various murine tumors and may be applied as a treatment of immunogenic human tumors. In addition, the findings indicate that IL-12 DNA is delivered into skin, but not into the tumor tissue following in vivo bombardment. Therefore, particle-mediated IL-12 gene therapy can be routinely applied to subcutaneous tumors or metastatic nodules without any surgical manipulations. Furthermore, the inventors found about 250 pg of IL-12 at the tumor bombardment site which is about 1/400 to 1/40,000 of the "therapeutic dose" of recombinant IL-12 (0.1-10μg) . Moreover, the therapeutic dose of IL-12 is also known to cause unacceptable toxicity levels. Therefore, in comparison with treatment with recombinant IL-12, treatment with the IL-12 gene therapy of the present invention is much less (if at all) toxic, and much less expensive. Thus it is demonstrated that circulating levels of cytokine IL-12 can be created in vivo by delivering into a patient in need of treatment for a tumor not quantities of IL-12 itself, but rather by delivering into the patient gene sequences causing expression of IL-12 in cells in the treated individual. The gene therapy method of the present invention enables the creation of an anti-tumor response in a treated individual without delivering IL-12 protein into the individual. SEOUENCE LISTING (1) GENERAL INFORMATION: ( i ) APPLICANT : Rakhmilevich, Alexander ( ii ) TITLE OF INVENTION : IL- 12 Gene Therapy of Tumors ( iii ) NUMBER OF SEQUENCES : 6 ( iv) CORRESPONDENCE ADDRESS : (A) ADDRESSEE : Robins & Associates (B) STREET : 90 Middlefield Road, Suite 200 (C) CITY : Menlo Park (D) STATE : CA ( E ) COUNTRY : USA ( F) ZIP : 94025 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: McCracken, Thomas P. (B) REGISTRATION NUMBER: 38,548 (C) REFERENCE/DOCKET NUMBER: 7011-0023.40 (ix ) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 415-325-7812 (B) TELEFAX: 415-325-7823 (2) INFORMATION FOR SEQ ID NO:1 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7287 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Plasmid DNA" (vii) IMMEDIATE SOURCE: (B) CLONE: pWRG3169 (ix) FEATURE: (A) NAME/KEY: promoter (B) LOCATION: 1..628 (ix) FEATURE: (A) NAME/KEY: iDNA (B) LOCATION: 629..810 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: join(953..1258, 1332..1673) (D) OTHER INFORMATION: /product= "p35 gene product" (ix) FEATURE: (A) NAME/KEY: polyA_site (B) LOCATION: 1797..2024 (ix) FEATURE: (A) NAME/KEY: promoter (B) LOCATION: 2110..2737 (ix) FEATURE: (A) NAME/KEY: iDNA (B) LOCATION: 2738..2919 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 2983..3990 (D) OTHER INFORMATION: /product= "p40 gene product" (ix) FEATURE: (A) NAME/KEY: polyA_site (B) LOCATION: 4075..4306 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC CCCGCCCATT 60 GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA GGGACTTTCC ATTGACGTCA 120 ATGGGTGGAG TATTTACGGT AAACTGCCCA CTTGGCAGTA CATCAAGTGT ATCATATGCC 180 AAGTACGCCC CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCCAGTA 240 CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA TCGCTATTAC 300 CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG ACTCACGGGG 360 ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG TTTTGGCACC AAAATCAACG 420 GGACTTTCCA AAATGTCGTA ACAACTCCGC CCCATTGACG CAAATGGGCG GTAGGCGTGT 480 ACGGTGGGAG GTCTATATAA GCAGAGCTCG TTTAGTGAAC CGTCAGATCG CCTGGAGACG 540 CCATCCACGC TGTTTTGACC TCCATAGAAG ACACCGGGAC CGATCCAGCC TCCGCGGCCG 600 GGAACGGTGC ATTGGAACGG ACTCTAGACT CCAGGAACTG AAAAACCAGA AAGTTAACTG 660 GTAAGTTTAG TCTTTTTGTC TTTTATTTCA GGTCCCGGAT CCGGTGGTGG TGCAAATCAA 720 AGAACTGCTC CTCAGTGGAT GTTGCCTTTA CTTCTAGGCC TGTACGGAAG TGTTACTTCT 780 GCTCTAAAAG CTGCGGAATT GTACCCGCGG CCGCAGCTTG GAATTCGATA ATTCGGCTTT 840 CCTGGGAAAG TCTGCCGGCT ATCCAGACAA TTATAAAAAT GTGTCTCCCA AGGTCAGCGT 900 TCCAACAGCC TCACCCTCGG CATCCAGCAG CTCCTCTCAG TGCCGGTCCA GC ATG 955 Met 1 TGT CAA TCA CGC TAC CTC CTC TTT TTG GCC ACC CTT GCC CTC CTA AAC 1003 Cys Gin Ser Arg Tyr Leu Leu Phe Leu Ala Thr Leu Ala Leu Leu Asn 5 10 15 CAC CTC AGT TTG GCC AGG GTC ATT CCA GTC TCT GGA CCT GCC AGG TGT 1051 His Leu Ser Leu Ala Arg Val lie Pro Val Ser Gly Pro Ala Arg Cys 20 25 30 CTT AGC CAG TCC CGA AAC CTG CTG AAG ACC ACA GAT GAC ATG GTG AAG 1099 Leu Ser Gin Ser Arg Asn Leu Leu Lys Thr Thr Asp Asp Met Val Lys 35 40 45 ACG GCC AGA GAA AAA CTG AAA CAT TAT TCC TGC ACT GCT GAA GAC ATC 1147 Thr Ala Arg Glu Lys Leu Lys His Tyr- Ser Cys Thr Ala Glu Asp lie 50 55 60 65 GAT CAT GAA GAC ATC ACA CGG GAC CAA ACC AGC ACA TTG AAG ACC TGT 1195 Asp His Glu Asp lie Thr Arg Asp Gin Thr Ser Thr Leu Lys Thr Cys 70 75 80 • TTA CCA CTG GAA CTA CAC AAG AAC GAG AGT TGC CTG GCT ACT AGA GAG 1243 Leu Pro Leu Glu Leu His Lys Asn Glu Ser Cys Leu Ala Thr Arg Glu 85 90 95 ACT TCT TCC ACA ACA GTAAGTAAGC ACTCTAAGGG TTCCTTCCCC ATGACGGATT 1298 Thr Ser Ser Thr Thr 100 CATAACACTG ATGCCTGGTC ATTCTTTCTC TAG AGA GGG AGC TGC CTG CCC CCA 1352 Arg Gly Ser Cys Leu Pro Pro 105 CAG AAG ACG TCT TTG ATG ATG ACC CTG TGC CTT GGT AGC ATC TAT GAG 1400 Gin Lys Thr Ser Leu Met Met Thr Leu Cys Leu Gly Ser lie Tyr Glu 110 115 120 125 GAC TTG AAG ATG TAC CAG ACA GAG TTC CAG GCC ATC AAC GCA GCA CTT 1448 Asp Leu Lys Met Tyr Gin Thr Glu Phe Gin Ala lie Asn Ala Ala Leu 130 135 140 CAG AAT CAC AAC CAT CAG CAG ATC ATT CTA GAC AAG GGC ATG CTG GTG 1496 Gin Asn His Asn His Gin Gin lie lie Leu Asp Lys Gly Met Leu Val 145 150 155 GCC ATC GAT GAG CTG ATG CAG TCT CTG AAT CAT AAT GGC GAG ACT CTG 1544 Ala He Asp Glu Leu Met Gin Ser Leu Asn His Asn Gly Glu Thr Leu 160 165 170 CGC CAG AAA CCT CCT GTG GGA GAA GCA GAC CCT TAC AGA GTG AAA ATG 1592 Arg Gin Lys Pro Pro Val Gly Glu Ala Asp Pro Tyr Arg Val Lys Met 175 180 185 AAG CTC TGC ATC CTG CTT CAC GCC TTC AGC ACC CGC GTC GTG ACC ATC 1640 Lys Leu Cys He Leu Leu His Ala Phe Ser Thr Arg Val Val Thr He 190 195 200 205 AAC AGG GTG ATG GGC TAT CTG AGC TCC GCC TGA AAGGCTCAAG GCCCTCTGCC 1693 Asn Arg Val Met Gly Tyr Leu Ser Ser Ala * 210 215 ACAGCGCCCT CCTCACACAG ATAGGAAAAG CCGAATTATC AAGCTTATCG ATACCGTCGA 1753 CCTCGAGGGG GGGCCCTATT CTATAGTGTC ACCTAAATGC TAGAGCTCGC TGATCAGCCT 1813 CGACTGTGCC TTCTAGTTGC CAGCCATCTG TTGTTTGCCC CTCCCCCGTG CCTTCCTTGA 1873 CCCTGGAAGG TGCCACTCCC ACTGTCCTTT CCTAATAAAA TGAGGAAATT GCATCGCATT 1933 GTCTGAGTAG GTGTCATTCT ATTCTGGGGG GTGGGGTGGG GCAGGACAGC AAGGGGGAGG 1993 ATTGGGAAGA CAATAGCAGG CATGCTGGGG ATGCGGTGGG CTCTATGGAA CCAGCTGGGG 2053 CTCGAGGGGG GGCCCGGTAC GGGCTGCAGG AATTCGAGCT TGCATGCCTG CAGGTCCGTT 2113 ACATAACTTA CGGTAAATGG CCCGCCTGGC TGACCGCCCA ACGACCCCCG CCCATTGACG 2173 TCAATAATGA CGTATGTTCC CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG 2233 GTGGAGTATT TACGGTAAAC TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT 2293 ACGCCCCCTA TTGACGTCAA TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG 2353 ACCTTATGGG ACTTTCCTAC TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG 2413 GTGATGCGGT TTTGGCAGTA CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT 2473 CCAAGTCTCC ACCCCATTGA CGTCAATGGG AGTTTGTTTT GGCACCAAAA TCAACGGGAC 2533 TTTCCAAAAT GTCGTAACAA CTCCGCCCCA TTGACGCAAA TGGGCGGTAG GCGTGTACGG 2593 TGGGAGGTCT ATATAAGCAG AGCTCGTTTA GTGAACCGTC AGATCGCCTG GAGACGCCAT 2653 CCACGCTGTT TTGACCTCCA TAGAAGACAC CGGGACCGAT CCAGCCTCCG CGGCCGGGAA 2713 CGGTGCATTG GAACGGACTC TAGACTCCAG GAACTGAAAA ACCAGAAAGT TAACTGGTAA 2773 GTTTAGTCTT TTTGTCTTTT ATTTCAGGTC CCGGATCCGG TGGTGGTGCA AATCAAAGAA 2833 CTGCTCCTCA GTGGATGTTG CCTTTACTTC TAGGCCTGTA CGGAAGTGTT ACTTCTGCTC 2893 TAAAAGCTGC GGAATTGTAC CCGCGGCCGC AGCTTGGAAT TCGATAATTC GGCTTGCACA 2953 TCAGACCAGG CAGCTCGCAG CAAAGCAAG ATG TGT CCT CAG AAG CTA ACC ATC 3006 Met Cys Pro Gin Lys Leu Thr He 1 5 TCC TGG TTT GCC ATC GTT TTG CTG GTG TCT CCA CTC ATG GCC ATG TGG 3054 Ser Trp Phe Ala He Val Leu Leu Val Ser Pro Leu Met Ala Met Trp 10 15 20 GAG CTG GAG AAA GAC GTT TAT GTT GTA GAG GTG GAC TGG ACT CCC GAT 3102 Glu Leu Glu Lys Asp Val Tyr Val Val Glu Val Asp Trp Thr Pro Asp 25 30 35 40 GCC CCT GGA GAA ACA GTG AAC CTC ACC TGT GAC ACG CCT GAA GAA GAT 3150 Ala Pro Gly Glu Thr Val Asn Leu Thr Cys Asp Thr Pro Glu Glu Asp 45 50 55 GAC ATC ACC TGG ACC TCA GAC CAG AGA CAT GGA GTC ATA GGC TCT GGA 3198 Asp He Thr Trp Thr Ser Asp Gin Arg His Gly Val He Gly Ser Gly 60 65 70 AAG ACC CTG ACC ATC ACT GTC AAA GAG TTT CTA GAT GCT GGC CAG TAC 3246 Lys Thr Leu Thr He Thr Val Lys Glu Phe Leu Asp Ala Gly Gin Tyr 75 80 85 ACC TGC CAC AAA GGA GGC GAG ACT CTG AGC CAC TCA CAT CTG CTG CTC 3294 Thr Cys His Lys Gly Gly Glu Thr Leu Ser His Ser His Leu Leu Leu 90 95 100 CAC AAG AAG GAA AAT GGA ATT TGG TCC ACT GAA ATT TTA AAA AAT TTC 3342 His Lys Lys Glu Asn Gly He Trp Ser Thr Glu He Leu Lys Asn Phe 105 110 115 120 AAA AAC AAG ACT TTC CTG AAG TGT GAA GCA CCA AAT TAC TCC GGA CGG 3390 Lys Asn Lys Thr Phe Leu Lys Cys Glu Ala Pro Asn Tyr Ser Gly Arg 125 130 135 TTC ACG TGC TCA TGG CTG GTG CAA AGA AAC ATG GAC TTG AAG TTC AAC 3438 Phe Thr Cys Ser Trp Leu Val Gin Arg Asn Met Asp Leu Lys Phe Asn 140 145 150 ATC AAG AGC AGT AGC AGT TCC CCT GAC TCT CGG GCA GTG ACA TGT GGA 3486 He Lys Ser Ser Ser Ser Ser Pro Asp Ser Arg Ala Val Thr Cys Gly 155 160 165 ATG GCG TCT CTG TCT GCA GAG AAG GTC ACA CTG GAC CAA AGG GAC TAT 3534 Met Ala Ser Leu Ser Ala Glu Lys Val Thr Leu Asp Gin Arg Asp Tyr 170 175 180 GAG AAG TAT TCA GTG TCC TGC CAG GAG GAT GTC ACC TGC CCA ACT GCC 3582 Glu Lys Tyr Ser Val Ser Cys Gin Glu Asp Val Thr Cys Pro Thr Ala 185 190 195 200 GAG GAG ACC CTG CCC ATT GAA CTG GCG TTG GAA GCA CGG CAG CAG AAT 3630 Glu Glu Thr Leu Pro He Glu Leu Ala Leu Glu Ala Arg Gin Gin Asn 205 210 215 AAA TAT GAG AAC TAC AGC ACC AGC TTC TTC ATC AGG GAC ATC ATC AAA 3678 Lys Tyr Glu Asn Tyr Ser Thr Ser Phe Phe He Arg Asp He He Lys 220 225 230 CCA GAC CCG CCC AAG AAC TTG CAG ATG AAG CCT TTG AAG AAC TCA CAG 3726 Pro Asp Pro Pro Lys Asn Leu Gin Met Lys Pro Leu Lys Asn Ser Gin 235 240 245 GTG GAG GTC AGC TGG GAG TAC CCT GAC TCC TGG AGC ACT CCC CAT TCC 3774 Val Glu Val Ser Trp Glu Tyr Pro Asp Ser Trp Ser Thr Pro His Ser 250 255 260 TAC TTC TCC CTC AAG TTC TTT GTT CGA ATC CAG CGC AAG AAA GAA AAG 3822 Tyr Phe Ser Leu Lys Phe Phe Val Arg He Gin Arg Lys Lys Glu Lys 265 270 275 280 ATG AAG GAG ACA GAG GAG GGG TGT AAC CAG AAA GGT GCG TTC CTC GTA 3870 Met Lys Glu Thr Glu Glu Gly Cys Asn Gin Lys Gly Ala Phe Leu Val .285 290 295 GAG AAG ACA TCT ACC GAA GTC CAA TGC AAA GGC GGG AAT GTC TGC GTG 3918 Glu Lys Thr Ser Thr Glu Val Gin Cys Lys Gly Gly Asn Val Cys Val 300 305 310 CAA GCT CAG GAT CGC TGT TAC AAT TCC TCG TGC AGC AAG TGG GCA TGT 3966 Gin Ala Gin Asp Arg Cys Tyr Asn Ser Ser Cys Ser Lys Trp Ala Cys 315 320 325 GTT CCC TGC AGG GTC CGA TCC TAG GATGCAACGT TGAAGCCGAA TTATCAAGCT 4020 Val Pro Cys Arg Val Arg Ser * 330 335 TATCGATACC GTCGACCTCG AGGGGGGGCC CTATTCTATA GTGTCACCTA AATGCTAGAG 4080 CTCGCTGATC AGCCTCGACT GTGCCTTCTA GTTGCCAGCC ATCTGTTGTT TGCCCCTCCC 4140 CCGTGCCTTC CTTGACCCTG GAAGGTGCCA CTCCCACTGT CCTTTCCTAA TAAAATGAGG 4200 AAATTGCATC GCATTGTCTG AGTAGGTGTC ATTCTATTCT GGGGGGTGGG GTGGGGCAGG 4260 ACAGCAAGGG GGAGGATTGG GAAGACAATA GCAGGCATGC TGGGGATGCG GTGGGCTCTA 4320 TGGAACCAGC TGGGGCTCGA GGGGGGGCCC GGTACCCAAT TCGCCCTATA GTGAGTCGTA 4380 TTACAATTCA CTGGCCGTCG TTTTACAACG TCGTGACTGG GAAAACCCTG GCGTTACCCA 4440 ACTTAATCGC CTTGCAGCAC ATCCCCCTTT CGCCAGCTGG CGTAATAGCG AAGAGGCCCG 4500 CACCGATCGC CCTTCCCAAC AGTTGCGCAG CCTGAATGGC GAATGGGACG CGCCCTGTAG 4560 CGGCGCATTA AGCGCGGCGG GTGTGGTGGT TACGCGCAGC GTGACCGCTA CACTTGCCAG 4620 CGCCCTAGCG CCCGCTCCTT TCGCTTTCTT CCCTTCCTTT CTCGCCACGT TCGCCGGCTT 4680 TCCCCGTCAA GCTCTAAATC GGGGGCTCCC TTTAGGGTTC CGATTTAGTG CTTTACGGCA 4740 CCTCGACCCC AAAAAACTTG ATTAGGGTGA TGGTTCACGT AGTGGGCCAT CGCCCTGATA 4800 GACGGTTTTT CGCCCTTTGA CGTTGGAGTC CACGTTCTTT AATAGTGGAC TCTTGTTCCA 4860 AACTGGAACA ACACTCAACC CTATCTCGGT CTATTCTTTT GATTTATAAG GGATTTTGCC 4 20 GATTTCGGCC TATTGGTTAA AAAATGAGCT GATTTAACAA AAATTTAACG CGAATTTTAA 4980 CAAAATATTA ACGCTTACAA TTTAGGTGGC ACTTTTCGGG GAAATGTGCG CGGAACCCCT 5040 ATTTGTTTAT TTTTCTAAAT ACATTCAAAT ATGTATCCGC TCATGAGACA ATAACCCTGA 5100 TAAATGCTTC AATAATATTG AAAAAGGAAG AGTATGAGTA TTCAACATTT CCGTGTCGCC 5160 CTTATTCCCT TTTTTGCGGC ATTTTGCCTT CCTGTTTTTG CTCACCCAGA AACGCTGGTG 5220 AAAGTAAAAG ATGCTGAAGA TCAGTTGGGT GCACGAGTGG GTTACATCGA ACTGGATCTC 5280 AACAGCGGTA AGATCCTTGA GAGTTTTCGC CCCGAAGAAC GTTTTCCAAT GATGAGCACT 5340 TTTAAAGTTC TGCTATGTGG CGCGGTATTA TCCCGTATTG ACGCCGGGCA AGAGCAACTC 5400 GGTCGCCGCA TACACTATTC TCAGAATGAC TTGGTTGAGT ACTCACCAGT CACAGAAAAG 5460 CATCTTACGG ATGGCATGAC AGTAAGAGAA TTATGCAGTG CTGCCATAAC CATGAGTGAT 5520 AACACTGCGG CCAACTTACT TCTGACAACG ATCGGAGGAC CGAAGGAGCT AACCGCTTTT 5580 TTGCACAACA TGGGGGATCA TGTAACTCGC CTTGATCGTT GGGAACCGGA GCTGAATGAA 5640 GCCATACCAA ACGACGAGCG TGACACCACG ATGCCTGTAG CAATGGCAAC AACGTTGCGC 5700 AAACTATTAA CTGGCGAACT ACTTACTCTA GCTTCCCGGC AACAATTAAT AGACTGGATG 5760 GAGGCGGATA AAGTTGCAGG ACCACTTCTG CGCTCGGCCC TTCCGGCTGG CTGGTTTATT 5820 GCTGATAAAT CTGGAGCCGG TGAGCGTGGG TCTCGCGGTA TCATTGCAGC ACTGGGGCCA 5880 GATGGTAAGC CCTCCCGTAT CGTAGTTATC TACACGACGG GGAGTCAGGC AACTATGGAT 5940 GAACGAAATA GACAGATCGC TGAGATAGGT GCCTCACTGA TTAAGCATTG GTAACTGTCA 6000 GACCAAGTTT ACTCATATAT ACTTTAGATT GATTTAAAAC TTCATTTTTA ATTTAAAAGG 6060 ATCTAGGTGA AGATCCTTTT TGATAATCTC ATGACCAAAA TCCCTTAACG TGAGTTTTCG 6120 TTCCACTGAG CGTCAGACCC CGTAGAAAAG ATCAAAGGAT CTTCTTGAGA TCCTTTTTTT 6180 CTGCGCGTAA TCTGCTGCTT GCAAACAAAA AAACCACCGC TACCAGCGGT GGTTTGTTTG 6240 CCGGATCAAG AGCTACCAAC TCTTTTTCCG AAGGTAACTG GCTTCAGCAG AGCGCAGATA 6300 CCAAATACTG TCCTTCTAGT GTAGCCGTAG TTAGGCCACC ACTTCAAGAA CTCTGTAGCA 6360 CCGCCTACAT ACCTCGCTCT GCTAATCCTG TTACCAGTGG CTGCTGCCAG TGGCGATAAG 6420 TCGTGTCTTA CCGGGTTGGA CTCAAGACGA TAGTTACCGG ATAAGGCGCA GCGGTCGGGC 6480 TGAACGGGGG GTTCGTGCAC ACAGCCCAGC TTGGAGCGAA CGACCTACAC CGAACTGAGA 6540 TACCTACAGC GTGAGCTATG AGAAAGCGCC ACGCTTCCCG AAGGGAGAAA GGCGGACAGG 6600 TATCCGGTAA GCGGCAGGGT CGGAACAGGA GAGCGCACGA GGGAGCTTCC AGGGGGAAAC 6660 GCCTGGTATC TTTATAGTCC TGTCGGGTTT CGCCACCTCT GACTTGAGCG TCGATTTTTG 6720 TGATGCTCGT CAGGGGGGCG GAGCCTATGG AAAAACGCCA GCAACGCGGC CTTTTTACGG 6780 TTCCTGGCCT TTTGCTGGCC TTTTGCTCAC ATGTTCTTTC CTGCGTTATC CCCTGATTCT 6840 GTGGATAACC GTATTACCGC CTTTGAGTGA GCTGATACCG CTCGCCGCAG CCGAACGACC 6900 GAGCGCAGCG AGTCAGTGAG CGAGGAAGCG GAAGAGCGCC CAATACGCAA ACCGCCTCTC 6960 CCCGCGCGTT GGCCGATTCA TTAATGCAGC TGGCACGACA GGTTTCCCGA CTGGAAAGCG 7020 GGCAGTGAGC GCAACGCAAT TAATGTGAGT TAGCTCACTC ATTAGGCACC CCAGGCTTTA 7080 CACTTTATGC TTCCGGCTCG TATGTTGTGT GGAATTGTGA GCGGATAACA ATTTCACACA 7140 GGAAACAGCT ATGACCATGA TTACGCCAAG CTCGAAATTA ACCCTCACTA AAGGGAACAA 7200 AAGCTGGAGC TCCACCGCGG TGGCGGCCGC TCTAGAACTA GTGGATCCCC CGGGCTGCAG 7260 GAATTCGAGC TTGCATGCCT GCAGGTC 7287 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 216 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Cys Gin Ser Arg Tyr Leu Leu Phe Leu Ala Thr Leu Ala Leu Leu 1 5 10 15 Asn His Leu Ser Leu Ala Arg Val He Pro Val Ser Gly Pro Ala Arg 20 25 30 Cys Leu Ser Gin Ser Arg Asn Leu Leu Lys Thr Thr Asp Asp Met Val 35 40 45 Lys Thr Ala Arg Glu Lys Leu Lys His Tyr Ser Cys Thr Ala Glu Asp 50 55 60 He Asp His Glu Asp He Thr Arg Asp Gin Thr Ser Thr Leu Lys Thr 65 70 75 80 Cys Leu Pro Leu Glu Leu His Lys Asn Glu Ser Cys Leu Ala Thr Arg 85 90 95 Glu Thr Ser Ser Thr Thr Arg Gly Ser Cys Leu Pro Pro Gin Lys Thr 100 105 110 Ser Leu Met Met Thr Leu Cys Leu Gly Ser He Tyr Glu Asp Leu Lys 115 120 125 Met Tyr Gin Thr Glu Phe Gin Ala He Asn Ala Ala Leu Gin Asn His 130 135 140 Asn His Gin Gin He He Leu Asp Lys Gly Met Leu Val Ala He Asp 145 150 155 160 Glu Leu Met Gin Ser Leu Asn His Asn Gly Glu Thr Leu Arg Gin Lys 165 170 175 Pro Pro Val Gly Glu Ala Asp Pro Tyr Arg Val Lys Met Lys Leu Cys 180 185 190 He Leu Leu His Ala Phe Ser Thr Arg Val Val Thr He Asn Arg Val 195 200 205 Met Gly Tyr Leu Ser Ser Ala * 210 215 (2) INFORMATION FOR SEQ ID NO:3 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 336 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: Met Cys Pro Gin Lys Leu Thr He Ser Trp Phe Ala He Val Leu Leu 1 5 10 15 Val Ser Pro Leu Met Ala Met Trp Glu Leu Glu Lys Asp Val Tyr Val 20 25 30 Val Glu Val Asp Trp Thr Pro Asp Ala Pro Gly Glu Thr Val Asn Leu 35 40 45 Thr Cys Asp Thr Pro Glu Glu Asp Asp He Thr Trp Thr Ser Asp Gin 50 55 60 Arg His Gly Val He Gly Ser Gly Lys Thr Leu Thr He Thr Val Lys 65 70 75 80 Glu Phe Leu Asp Ala Gly Gin Tyr Thr Cys His Lys Gly Gly Glu Thr 85 90 95 Leu Ser His Ser His Leu Leu Leu His Lys Lys Glu Asn Gly He Trp 100 105 110 Ser Thr Glu He Leu Lys Asn Phe Lys Asn Lys Thr Phe Leu Lys Cys 115 120 125 Glu Ala Pro Asn Tyr Ser Gly Arg Phe Thr Cys Ser Trp Leu Val Gin 130 135 140 Arg Asn Met Asp Leu Lys Phe Asn He Lys Ser Ser Ser Ser Ser Pro 145 150 155 160 Asp Ser Arg Ala Val Thr Cys Gly Met Ala Ser Leu Ser Ala Glu Lys 165 170 175 Val .Thr Leu Asp Gin Arg Asp Tyr Glu Lys Tyr Ser Val Ser Cys Gin 180 185 190 Glu Asp Val Thr Cys Pro Thr Ala Glu Glu Thr Leu Pro He Glu Leu 195 200 205 Ala Leu Glu Ala Arg Gin Gin Asn Lys Tyr Glu Asn Tyr Ser Thr Ser 210 215 220 Phe Phe He Arg Asp He He Lys Pro Asp Pro Pro Lys Asn Leu Gin 225 230 235 240 Met Lys Pro Leu Lys Asn Ser Gin Val Glu Val Ser Trp Glu Tyr Pro 245 250 255 Asp Ser Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Lys Phe Phe Val 260 265 270 Arg He Gin Arg Lys Lys Glu Lys Met Lys Glu Thr Glu Glu Gly Cys 275 280 285 Asn Gin Lys Gly Ala Phe Leu Val Glu Lys Thr Ser Thr Glu Val Gin 290 295 300 Cys Lys Gly Gly Asn Val Cys Val Gin Ala Gin Asp Arg Cys Tyr Asn 305 310 315 320 Ser Ser Cys Ser Lys Trp Ala Cys Val Pro Cys Arg Val Arg Ser * 325 330 335 (2) INFORMATION FOR SEQ ID NO:4 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6295 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "plasmid pWRG3196" (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: join(955..1260, 1334..1675) (D) OTHER INFORMATION : /product= "p35 gene product " ( ix) FEATURE : (A) NAME/KEY: CDS (B) LOCATION: 2377..3384 (D) OTHER INFORMATION: /product= "p40 gene product" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4 : GAATTCGAGC TTGCATGCCT GCAGGTCGTT ACATAACTTA CGGTAAATGG CCCGCCTGGC 60 TGACCGCCCA ACGACCCCCG CCCATTGACG TCAATAATGA CGTATGTTCC CATAGTAACG 120 CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT TACGGTAAAC TGCCCACTTG 180 GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA TTGACGTCAA TGACGGTAAA 240 TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCCTAC TTGGCAGTAC 300 ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCGGT TTTGGCAGTA CATCAATGGG 360 CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC ACCCCATTGA CGTCAATGGG 420 AGTTTGTTTT GGCACCAAAA TCAACGGGAC TTTCCAAAAT GTCGTAACAA CTCCGCCCCA 480 TTGACGCAAA TGGGCGGTAG GCGTGTACGG TGGGAGGTCT ATATAAGCAG AGCTCGTTTA 540 GTGAACCGTC AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA TAGAAGACAC 600 CGGGACCGAT CCAGCCTCCG GACTCTAGAG GATCCGGTAC TCGAGGAACT GAAAAACCAG 660 AAAGTTAACT GGTAAGTTTA GTCTTTTTGT CTTTTATTTC AGGTCCCGGA TCCGGTGGTG 720 GTGCAAATCA AAGAACTGCT CCTCAGTGGA TGTTGCCTTT ACTTCTAGGC CTGTACGGAA 780 GTGTTACTTC TGCTCTAAAA GCTGCGGAAT TGTACCCGCG GCCGGTGGTT AAATTCGGCT 840 TTCCTGGGAA AGTCTGCCGG CTATCCAGAC AATTATAAAA ATGTGTCTCC CAAGGTCAGC 900 GTTCCAACAG CCTCACCCTC GGCATCCAGC AGCTCCTCTC AGTGCCGGTC CAGC ATG 957 Met 1 TGT CAA TCA CGC TAC CTC CTC TTT TTG GCC ACC CTT GCC CTC CTA AAC 1005 Cys Gin Ser Arg Tyr Leu Leu Phe Leu Ala Thr Leu Ala Leu Leu Asn 5 10 15 CAC CTC AGT TTG GCC AGG GTC ATT CCA GTC TCT GGA CCT GCC AGG TGT 1053 His Leu Ser Leu Ala Arg Val He Pro Val Ser Gly Pro Ala Arg Cys 20 25 30 CTT AGC CAG TCC CGA AAC CTG CTG AAG ACC ACA GAT GAC ATG GTG AAG 1101 Leu Ser Gin Ser Arg Asn Leu Leu Lys Thr Thr Asp Asp Met Val Lys 35 40 45 ACG GCC AGA GAA AAA CTG AAA CAT TAT TCC TGC ACT GCT GAA GAC ATC 1149 Thr Ala Arg Glu Lys Leu Lys His Tyr Ser Cys Thr Ala Glu Asp He 50 55 60 65 GAT CAT GAA GAC ATC ACA CGG GAC CAA ACC AGC ACA TTG AAG ACC TGT 1197 Asp His Glu Asp He Thr Arg Asp Gin Thr Ser Thr Leu Lys Thr Cys 70 75 80 TTA CCA CTG GAA CTA CAC AAG AAC GAG AGT TGC CTG GCT ACT AGA GAG 1245 Leu Pro Leu Glu Leu His Lys Asn Glu Ser Cys Leu Ala Thr Arg Glu 85 90 95 ACT TCT TCC ACA ACA GTAAGTAAGC ACTCTAAGGG TTCCTTCCCC ATGACGGATT 1300 Thr Ser Ser Thr Thr 100 CATAACACTG ATGCCTGGTC ATTCTTTCTC TAG AGA GGG AGC TGC CTG CCC CCA .1354 Arg Gly Ser Cys Leu Pro Pro 105 CAG AAG ACG TCT TTG ATG ATG ACC CTG TGC CTT GGT AGC ATC TAT GAG 1402 Gin Lys Thr Ser Leu Met Met Thr Leu Cys Leu Gly Ser He Tyr Glu 110 115 120 125 GAC TTG AAG ATG TAC CAG ACA GAG TTC CAG GCC ATC AAC GCA GCA CTT 1450 Asp Leu Lys Met Tyr Gin Thr Glu Phe Gin Ala He Asn Ala Ala Leu 130 135 140 CAG AAT CAC AAC CAT CAG CAG ATC ATT CTA GAC AAG GGC ATG CTG GTG 1498 Gin Asn His Asn His Gin Gin He He Leu Asp Lys Gly Met Leu Val 145 150 155 GCC \TC GAT GAG CTG ATG CAG TCT CTG AAT CAT AAT GGC GAG ACT CTG 1546 Ala He Asp Glu Leu Met Gin Ser Leu Asn His Asn Gly Glu Thr Leu 160 165 170 CGC CAG AAA CCT CCT GTG GGA GAA GCA GAC CCT TAC AGA GTG AAA ATG 1594 Arg Gin Lys Pro Pro Val Gly Glu Ala Asp Pro Tyr Arg Val Lys Met 175 180 185 AAG CTC TGC ATC CTG CTT CAC GCC TTC AGC ACC CGC GTC GTG ACC ATC 1642 Lys Leu Cys He Leu Leu His Ala ' Phe Ser Thr Arg Val Val Thr He 190 195 200 205 AAC AGG GTG ATG GGC TAT CTG AGC TCC GCC TGA AAGGCTCAAG GCCCTCTGCC 1695 Asn Arg Val Met Gly Tyr Leu Ser Ser Ala * 210 215 ACAGCGCCCT CCTCACACAG ATAGGAAAAG CCGAATTTAA GATATCACTA GTGAATTCCG 1755 CCCCTCTCCC TCCCCCCCCC CTAACGTTAC TGGCCGAAGC CGCTTGGAAT AAGGCCGGTG 1815 TGCGTTTGTC TATATGTTAT TTTCCACCAT ATTGCCGTCT TTTGGCAATG TGAGGGCCCG 1875 GAAACCTGGC CCTGTCTTCT TGACGAGCAT TCCTAGGGGT CTTTCCCCTC TCGCCAAAGG 1935 AATGCAAGGT CTGTTGAATG TCGTGAAGGA AGCAGTTCCT CTGGAAGCTT CTTGAAGACA 1995 AACAACGTCT GTAGCGACCC TTTGCAGGCA GCGGAACCCC CCACCTGGCG ACAGGTGCCT 2055 CTGCGGCCAA AAGCCACGTG TATAAGATAC ACCTGCAAAG GCGGCACAAC CCCAGTGCCA 2115 CGTTGTGAGT TGGATAGTTG TGGAAAGAGT CAAATGGCTC TCCTCAAGCG TATTCAACAA 2175 GGGGCTGAAG GATGCCCAGA AGGTACCCCA TTGTATGGGA TCTGATCTGG GGCCTCGGTG 2235 CACATGCTTT ACATGTGTTT AGTCGAGGTT AAAAAACGTC TAGGCCCCCC GAACCACGGG 2295 GACGTGGTTT TCCTTTGAAA AACACGATGA TAATCCCAAT TCGGCTTGCA CATCAGACCA 2355 GGCAGCTCGC AGCAAAGCAA G ATG TGT CCT CAG AAG CTA ACC ATC TCC TGG 2406 Met Cys Pro Gin Lys Leu Thr He Ser Trp 1 5 10 TTT GCC ATC GTT TTG CTG GTG TCT CCA CTC ATG GCC ATG TGG GAG CTG 2454 Phe Ala He Val Leu Leu Val Ser Pro Leu Met Ala Met Trp Glu Leu 15 20 25 GAG AAA GAC GTT TAT GTT GTA GAG GTG GAC TGG ACT CCC GAT GCC CCT 2502 Glu Lys Asp Val Tyr Val Val Glu Val Asp Trp Thr Pro Asp Ala Pro 30 35 40 GGA GAA ACA GTG AAC CTC ACC TGT GAC ACG CCT GAA GAA GAT GAC ATC 2550 Gly Glu Thr Val Asn Leu Thr Cys Asp Thr Pro Glu Glu Asp Asp He 45 50 55 ACC TGG ACC TCA GAC CAG AGA CAT GGA GTC ATA GGC TCT GGA AAG ACC 2598 Thr Trp Thr Ser Asp Gin Arg His Gly Val He Gly Ser Gly Lys Thr 60 65 70 CTG ACC ATC ACT GTC AAA GAG TTT CTA GAT GCT GGC CAG TAC ACC TGC 2646 Leu Thr He Thr Val Lys Glu Phe Leu Asp Ala Gly Gin Tyr Thr Cys 75 80 85 90 CAC AAA GGA GGC GAG ACT CTG AGC CAC TCA CAT CTG CTG CTC CAC AAG 2694 His Lys Gly Gly Glu Thr Leu Ser His Ser His Leu Leu Leu His Lys 95 100 105 AAG GAA AAT GGA ATT TGG TCC ACT GAA ATT TTA AAA AAT TTC AAA AAC 2742 Lys Glu Asn Gly He Trp Ser Thr Glu He Leu Lys Asn Phe Lys Asn 110 115 120 AAG ACT TTC CTG AAG TGT GAA GCA CCA AAT TAC TCC GGA CGG TTC ACG 2790 Lys Thr Phe Leu Lys Cys Glu Ala Pro Asn Tyr Ser Gly Arg Phe Thr 125 130 135 TGC TCA TGG CTG GTG CAA AGA AAC ATG GAC TTG AAG TTC AAC ATC AAG 2838 Cys Ser Trp Leu Val Gin Arg Asn Met Asp Leu Lys Phe Asn He Lys 140 145 150 AGC AGT AGC AGT TCC CCT GAC TCT CGG GCA GTG ACA TGT GGA ATG GCG 2886 Ser Ser Ser Ser Ser Pro Asp Ser Arg Ala Val Thr Cys Gly Met Ala 155 160 165 170 TCT CTG TCT GCA GAG AAG GTC ACA CTG GAC CAA AGG GAC TAT GAG AAG 2934 Ser Leu Ser Ala Glu Lys Val Thr Leu Asp Gin Arg Asp Tyr Glu Lys 175 180 185 TAT TCA GTG TCC TGC CAG GAG GAT GTC ACC TGC CCA ACT GCC GAG GAG 2982 Tyr Ser Val Ser Cys Gin Glu Asp Val Thr Cys Pro Thr Ala Glu Glu 190 195 200 ACC CTG CCC ATT GAA CTG GCG TTG GAA GCA CGG CAG CAG AAT AAA TAT 3030 Thr Leu Pro He Glu Leu Ala Leu Glu Ala Arg Gin Gin Asn Lys Tyr 205 210 215 GAG AAC TAC AGC ACC AGC TTC TTC ATC AGG GAC ATC ATC AAA CCA GAC 3078 Glu Asn Tyr Ser Thr Ser Phe Phe He Arg Asp He He Lys Pro Asp 220 225 230 CCG CCC AAG AAC TTG CAG ATG AAG CCT TTG AAG AAC TCA CAG GTG GAG 3126 Pro Pro Lys Asn Leu Gin Met Lys Pro Leu Lys Asn Ser Gin Val Glu 235 240 245 250 GTC AGC TGG GAG TAC CCT GAC TCC TGG AGC ACT CCC CAT TCC TAC TTC 3174 Val Ser Trp Glu Tyr Pro Asp Ser Trp Ser Thr Pro His Ser Tyr Phe 255 260 265 TCC CTC AAG TTC TTT GTT CGA ATC CAG CGC AAG AAA GAA AAG ATG AAG 3222 Ser Leu Lys Phe Phe Val Arg He Gin Arg Lys Lys Glu Lys Met Lys 270 275 280 GAG ACA GAG GAG GGG TGT AAC CAG AAA GGT GCG TTC CTC GTA GAG AAG 3270 Glu Thr Glu Glu Gly Cys Asn Gin Lys Gly Ala Phe Leu Val Glu Lys 285 290 295 ACA TCT ACC GAA GTC CAA TGC AAA GGC GGG AAT GTC TGC GTG CAA GCT 3318 Thr Ser Thr Glu Val Gin Cys Lys Gly Gly Asn Val Cys Val Gin Ala 300 305 310 CAG GAT CGC TGT TAC AAT TCC TCG TGC AGC AAG TGG GCA TGT GTT CCC 3366 Gin Asp Arg Cys Tyr Asn Ser Ser Cys Ser Lys Trp Ala Cys Val Pro 315 320 325 330 TGC AGG GTC CGA TCC TAG GATGCAACGT TGAAGCCGAA TTGGGCGGCC 3414 Cys Arg Val Arg Ser * 335 GCATGCATCC CTCCGCGGGG ATCCAGACAT GATAAGATAC ATTGATGAGT TTGGACAAAC 3474 CACAACTAGA ATGCAGTGAA AAAAATGCTT TATTTGTGAA ATTTGTGATG CTATTGCTTT 3534 ATTTGTAACC ATTATAAGCT GCAATAAACA AGTTAACAAC AACAATTGCA TTCATTTTAT 3594 GTTTCAGGTT CAGGGGGAGG TGTGGGAGGT TTTTTCGGAT CCTCTAGAGT CGACCTGCAG 3654 GCATGCAAGC TTGGCGTAAT CATGGTCATA GCTGTTTCCT GTGTGAAATT GTTATCCGCT 3714 CACAATTCCA CACAACATAC GAGCCGGAAG CATAAAGTGT AAAGCCTGGG GTGCCTAATG 3774 AGTGAGCTAA CTCACATTAA TTGCGTTGCG CTCACTGCCC GCTTTCCAGT CGGGAAACCT 3834 GTCGTGCCAG CTGCATTAAT GAATCGGCCA ACGCGCGGGG AGAGGCGGTT TGCGTATTGG 3894 GCGCTCTTCC GCTTCCTCGC TCACTGACTC GCTGCGCTCG GTCGTTCGGC TGCGGCGAGC 3954 GGTATCAGCT CACTCAAAGG CGGTAATACG GTTATCCACA GAATCAGGGG ATAACGCAGG 4014 AAAGAACATG TGAGCAAAAG GCCAGCAAAA GGCCAGGAAC CGTAAAAAGG CCGCGTTGCT 4074 GGCGTTTTTC CATAGGCTCC GCCCCCCTGA CGAGCATCAC AAAAATCGAC GCTCAAGTCA 4134 GAGGTGGCGA AACCCGACAG GACTATAAAG ATACCAGGCG TTTCCCCCTG GAAGCTCCCT 4194 CGTGCGCTCT CCTGTTCCGA CCCTGCCGCT TACCGGATAC CTGTCCGCCT TTCTCCCTTC 4254 GGGAAGCGTG GCGCTTTCTC ATAGCTCACG CTGTAGGTAT CTCAGTTCGG TGTAGGTCGT 4314 TCGCTCCAAG CTGGGCTGTG TGCACGAACC CCCCGTTCAG CCCGACCGCT GCGCCTTATC 4374 CGGTAACTAT CGTCTTGAGT CCAACCCGGT AAGACACGAC TTATCGCCAC TGGCAGCAGC 4434 CACTGGTAAC AGGATTAGCA GAGCGAGGTA TGTAGGCGGT GCTACAGAGT TCTTGAAGTG 4494 GTGGCCTAAC TACGGCTACA CTAGAAGGAC AGTATTTGGT ATCTGCGCTC TGCTGAAGCC 4554 AGTTACCTTC GGAAAAAGAG TTGGTAGCTC TTGATCCGGC AAACAAACCA CCGCTGGTAG 4614 CGGTGGTTTT TTTGTTTGCA AGCAGCAGAT TACGCGCAGA AAAAAAGGAT CTCAAGAAGA 4674 TCCTTTGATC TTTTCTACGG GGTCTGACGC TCAGTGGAAC GAAAACTCAC GTTAAGGGAT 4734 TTTGGTCATG AGATTATCAA AAAGGATCTT CACCTAGATC CTTTTAAATT AAAAATGAAG 4794 TTTTAAATCA ATCTAAAGTA TATATGAGTA AACTTGGTCT GACAGTTACC AATGCTTAAT 4854 CAGTGAGGCA CCTATCTCAG CGATCTGTCT ATTTCGTTCA TCCATAGTTG CCTGACTCCC 4914 CGTCGTGTAG ATAACTACGA TACGGGAGGG CTTACCATCT GGCCCCAGTG CTGCAATGAT 4974 ACCGCGAGAC CCACGCTCAC CGGCTCCAGA TTTATCAGCA ATAAACCAGC CAGCCGGAAG 5034 GGCCGAGCGC AGAAGTGGTC CTGCAACTTT ATCCGCCTCC ATCCAGTCTA TTAATTGTTG 5094 CCGGGAAGCT AGAGTAAGTA GTTCGCCAGT TAATAGTTTG CGCAACGTTG TTGCCATTGC 5154 TACAGGCATC GTGGTGTCAC GCTCGTCGTT TGGTATGGCT TCATTCAGCT CCGGTTCCCA 5214 ACGATCAAGG CGAGTTACAT GATCCCCCAT GTTGTGCAAA AAAGCGGTTA GCTCCTTCGG 5274 TCCTCCGATC GTTGTCAGAA GTAAGTTGGC CGCAGTGTTA TCACTCATGG TTATGGCAGC 5334 ACTGCATAAT TCTCTTACTG TCATGCCATC CGTAAGATGC TTTTCTGTGA CTGGTGAGTA 5394 CTCAACCAAG TCATTCTGAG AATAGTGTAT GCGGCGACCG AGTTGCTCTT GCCCGGCGTC 5454 AATACGGGAT AATACCGCGC CACATAGCAG AACTTTAAAA GTGCTCATCA TTGGAAAACG 5514 TTCTTCGGGG CGAAAACTCT CAAGGATCTT ACCGCTGTTG AGATCCAGTT CGATGTAACC 5574 CACTCGTGCA CCCAACTGAT CTTCAGCATC TTTTACTTTC ACCAGCGTTT CTGGGTGAGC 5634 AAAAACAGGA AGGCAAAATG CCGCAAAAAA GGGAATAAGG GCGACACGGA AATGTTGAAT 5694 ACTCATACTC TTCCTTTTTC AATATTATTG AAGCATTTAT CAGGGTTATT GTCTCATGAG 5754 CGGATACATA TTTGAATGTA TTTAGAAAAA TAAACAAATA GGGGTTCCGC GCACATTTCC 5814 CCGAAAAGTG CCACCTGACG TCTAAGAAAC CATTATTATC ATGACATTAA CCTATAAAAA 5874 TAGGCGTATC ACGAGGCCCT TTCGTCTCGC GCGTTTCGGT GATGACGGTG AAAACCTCTG 5934 ACACATGCAG CTCCCGGAGA CGGTCACAGC TTGTCTGTAA GCGGATGCCG GGAGCAGACA 5994 AGCCCGTCAG GGCGCGTCAG CGGGTGTTGG CGGGTGTCGG GGCTGGCTTA ACTATGCGGC 6054 ATCAGAGCAG ATTGTACTGA GAGTGCACCA TATGCGGTGT GAAATACCGC ACAGATGCGT 6114 AAGGAGAAAA TACCGCATCA GGCGCCATTC GCCATTCAGG CTGCGCAACT GTTGGGAAGG 6174 GCGATCGGTG CGGGCCTCTT CGCTATTACG CCAGCTGGCG AAAGGGGGAT GTGCTGCAAG 6234 GCGATTAAGT TGGGTAACGC CAGGGTTTTC CCAGTCACGA CGTTGTAAAA CGACGGCCAG 6294 T 6295 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 216 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5 : Met Cys Gin Ser Arg Tyr Leu Leu Phe Leu Ala Thr Leu Ala Leu Leu 1 5 10 15 Asn His Leu Ser Leu Ala Arg Val He Pro Val Ser Gly Pro Ala Arg 20 25 30 Cys Leu Ser Gin Ser Arg Asn Leu Leu Lys Thr Thr Asp Asp Met Val 35 40 45 Lys Thr Ala Arg Glu Lys Leu Lys His Tyr Ser Cys Thr Ala Glu Asp 50 55 60 He Asp His Glu Asp He Thr Arg Asp Gin Thr Ser Thr Leu Lys Thr 65 70 75 80 Cys Leu Pro Leu Glu Leu His Lys Asn Glu Ser Cys Leu Ala Thr Arg 85 90 95 Glu Thr Ser Ser Thr Thr Arg Gly Ser Cys Leu Pro Pro Gin Lys Thr 100 105 110 Ser Leu Met Met Thr Leu Cys Leu Gly Ser He Tyr Glu Asp Leu Lys 115 120 125 Met Tyr Gin Thr Glu Phe Gin Ala He Asn Ala Ala Leu Gin Asn His 130 135 140 Asn His Gin Gin He He Leu Asp Lys Gly Met Leu Val Ala He Asp 145 150 155 160 Glu Leu Met Gin Ser Leu Asn His Asn Gly Glu Thr Leu Arg Gin Lys 165 170 175 Pro Pro Val Gly Glu Ala Asp Pro Tyr Arg Val Lys Met Lys Leu Cys 180 185 190 He Leu Leu His Ala Phe Ser Thr Arg Val Val Thr He Asn Arg Val 195 200 205 Met Gly Tyr Leu Ser Ser Ala * 210 215 (2) INFORMATION FOR SEQ ID NO:6 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 336 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6 : Met Cys Pro Gin Lys Leu Thr He Ser Trp Phe Ala He Val Leu Leu 1 5 10 15 Val Ser Pro Leu Met Ala Met Trp Glu Leu Glu Lys Asp Val Tyr Val 20 25 30 Val Glu Val Asp Trp Thr Pro Asp Ala Pro Gly Glu Thr Val Asn Leu 35 40 45 Thr Cys Asp Thr Pro Glu Glu Asp Asp He Thr Trp Thr Ser Asp Gin 50 55 60 Arg His Gly Val He Gly Ser Gly Lys Thr Leu Thr He Thr Val Lys 65 70 75 80 Glu Phe Leu Asp Ala Gly Gin Tyr Thr Cys His Lys Gly Gly Glu Thr 85 90 95 Leu Ser His Ser His Leu Leu Leu His Lys Lys Glu Asn Gly He Trp 100 105 110 Ser Thr Glu He Leu Lys Asn Phe Lys Asn Lys Thr Phe Leu Lys Cys 115 120 125 Glu Ala Pro Asn Tyr Ser Gly Arg Phe Thr Cys Ser Trp Leu Val Gin 130 135 140 Arg Asn Met Asp Leu Lys Phe Asn He Lys Ser Ser Ser Ser Ser Pro 145 150 155 160 Asp Ser Arg Ala Val Thr Cys Gly Met Ala Ser Leu Ser Ala Glu Lys 165 170 175 Val Thr Leu Asp Gin Arg Asp Tyr Glu Lys Tyr Ser Val Ser Cys Gin 180 185 190 Glu Asp Val Thr Cys Pro Thr Ala Glu Glu Thr Leu Pro He Glu Leu 195 200 205 Ala Leu Glu Ala Arg Gin Gin Asn Lys Tyr Glu Asn Tyr Ser Thr Ser 210 215 220 Phe Phe He Arg Asp He He Lys Pro Asp Pro Pro Lys Asn Leu Gin 225 230 235 240 Met Lys Pro Leu Lys Asn Ser Gin Val Glu Val Ser Trp Glu Tyr Pro 245 250 255 Asp Ser Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Lys Phe Phe Val 260 265 270 Arg He Gin Arg Lys Lys Glu Lys Met Lys Glu Thr Glu Glu Gly Cys 275 280 285 Asn Gin Lys Gly Ala Phe Leu Val Glu Lys Thr Ser Thr Glu Val Gin 290 295 300 Cys Lys Gly Gly Asn Val Cys Val Gin Ala Gin Asp Arg Cys Tyr Asn 305 310 315 320 Ser Ser Cys Ser Lys Trp Ala Cys Val Pro Cys Arg Val Arg Ser * 325 330 335

Claims: CLAIMS 1. A method of treating tumors in a mammal, the method comprising: (a) preparing copies of an expressible foreign genetic construction comprising a promoter operative in epidermal cells of the mammal, a DNA sequence encoding a p35 subunit of cytokine IL-12, and a DNA sequence encoding a p40 subunit of cytokine IL-12; and (b) delivering the copies of the foreign genetic construction into target cells of the mammal in vivo. 2. A method as claimed in claim 1 wherein the delivering step comprises the steps of: coating the copies of the foreign genetic construction onto carrier particles small in size in relation to the size of the cells of the mammal; and accelerating the coated carrier particles into target cells of the mammal in vivo. 3. A method as claimed in Claim 1 wherein the carrier particles are accelerated by a gaseous discharge toward the mammal . 4. A method as claimed in Claim 1 wherein the DNA sequence encoding the p35 subunit encodes SEQ ID NO:2 and the DNA sequence encoding the p40 subunit encodes SEQ ID NO:3. 5. A method as claimed in Claim 1, wherein the DNA sequence encoding the p35 subunit is SEQ ID N0:1 at bases 953-1258 and 1332-1673 and the DNA sequence encoding the p40 subunit is SEQ ID N0:1 at bases 2377- 3381. 6. A method as claimed in Claim 1, wherein the DNA sequence encoding the p35 subunit is sufficiently homologous to SEQ ID N0:1 at bases 953-1258 and 1332- 1673 so as to encode an IL-12 p35 subunit, and the DNA sequence encoding the p40 subunit is sufficiently homologous to SEQ ID N0:1 at bases 2377-3381 so as to encode an IL-12 p40 subunit. 7. A method as claimed in claim 6 wherein the genetic construct is pWRG3169. 8. A method as claimed in claim 6 wherein the genetic construct is pWRG3196.

Inventors: RAKHMILEVICH ALEXANDER L, YANG NING-SUN, RAKHMILEVICH, ALEXANDER, L., YANG, NING-SUN
Applicants: AURAGEN INC, AURAGEN, INC.
Application year: 1997
Main classification: A61K48
IPC codes: A61K38, A61K48, C12N15